Key Drivers
- Margin Stability
- Cash Strength
- Premium Pricing
AIAI Summary
IRMD remains a high-quality, cash-generative medtech franchise, but Q1 mostly confirmed durability rather than a new catalyst, so upside now hinges on whether the 3870 rollout and MRI-demand growth can justify an already stretched valuation; otherwise, the stock is likely to stay range-bound until execution proves the next leg of compounding.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Stability
- •Cash Strength
- •Premium Pricing
IRMD shows durable high margins, strong cash generation, and a debt-free, highly liquid balance sheet, but its premium valuation and high payout ratio limit upside and leave little margin for error.
Price Behavior
Key Price Behavior Insights:
- •Base forming
- •87 resistance
- •83 support
IRMD has been in a short-term downtrend over the last month, but the rebound from $83-$84 support into the mid-$86s suggests a basing attempt unless it breaks below support or clears $87 resistance.
Fell from about $93.49 to $83.25, then rebounded to $86.44, indicating a possible base-building bounce
Sentiment & News
Key News Insights:
- •Revenue Growth
- •EPS Beat
- •Guidance Reaffirmed
IRADIMED delivered a strong Q1 2026 beat with 13% revenue growth, record EPS, a raised dividend, and reaffirmed guidance, helping lift the stock.
The results point to improving operational momentum and support a constructive near-term outlook for IRMD
Similar Companies in Healthcare
Other companies in the same sector with AI ratings